MDGL
Madrigal Pharmaceuticals, Inc. Common Stock
PHARMACEUTICAL PREPARATIONS
Best Pharmaceutical Stocks 2026 →
Madrigal Pharmaceuticals (MDGL) Stock: Buy, Sell, or Hold?
$432.60
-0.19 (-0.04%)
▼
5d:
+9.15%
30d:
-7.4%
90d:
-19.32%
QUANTITATIVE VERDICT
BUY
HIGH Confidence (91%)
Quality Score
55/100
Position
OVERSOLD
30-Day Fair Range
$421.50 – $491.07
Position: OVERSOLD
Forward P/E & Valuation
38.6x
CHEAP
vs 85.5x historical avg
Wall Street Target
$688.94
+59.3% upside
Options IV & Volume
HIGH Vol
HIGH volume confirmation
Support / Resistance
$353.54 / $482.73
Trend: Strong Downtrend
Executive Thesis & Bottom Line
Forward Earnings Fair Value & Price Prediction →
✅ BUY SIGNAL: MDGL trading at deep discount. Market pricing in -23.3% annual earnings decline, creating value opportunity for patient investors.
Get Alerted When MDGL Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$392.68
Based on 7.0% avg growth
INTRINSIC VALUE TODAY
$243.82
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 25.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: MDGL is currently trading at $432.60, which is considered oversold relative to its 30-day fair value range of $421.50 to $491.07. From a valuation perspective, the stock is trading at a discount (Forward PE: 38.6) compared to its historical average (85.5). Remarkably, the market is currently pricing in an annual earnings decline of 23.3% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, MDGL is in a strong downtrend. Immediate support is located at $353.54, while resistance sits at $482.73.
Market Sentiment: MDGL scores 76/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $688.94 (+59.3%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, MDGL is in a strong downtrend. Immediate support is located at $353.54, while resistance sits at $482.73.
Market Sentiment: MDGL scores 76/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $688.94 (+59.3%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$421.50 -
$491.07
Company Quality Score
55/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
90.5%
Trading Range & Key Levels
30-Day Trading Range
$421.50 -
$491.07
Current vs Trading Range
OVERSOLD
Support Level
$353.54
Resistance Level
$482.73
Current Trend
Strong Downtrend
Technical data as of
Nov 10, 2026
Quantitative Signal Breakdown
- BULLISH: Price oversold vs 30-day range
- BULLISH: Strong technical setup (76/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 59.3% below Wall St target ($688.94)
- BULLISH: Bottoming setup score 76/100 — corrected, stabilizing, and turning up
Fundamental Context
Forward P/E (Next Year Est.)
38.59
Wall Street Target
$688.94
(+59.3%)
Revenue Growth (YoY)
50.1%
Profit Margin
-10.9%
Valuation Discount vs History
-23.3% cheaper
PE vs Historical
38.6 vs 85.5
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-23.3%
(market-implied from PE analysis)
1-Year Target
$389.34
(-10%)
2-Year Target
$350.41
(-19%)
3-Year Target
$315.37
(-27%)
3-Yr Target (if PE normalizes)
(PE: 39→86)
$698.71
(+62%)
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 38.6 to 85.5
Stabilization Target:
$958.46
(+121.6%)
PE Expansion Potential:
+121.6%
Share MDGL Analysis
Share this live MDGL analysis (with rich preview card) to Reddit, StockTwits, X, or embed the chart on your blog.
bloggers & journalists: you are free to use our charts with attribution.Reddit & Retail Trader Sentiment (MDGL)
Bearish
2 Retail Mentions
Reddit / WSB Comments
1
Bullish
StockTwits Volume
1 msgs
24h retail stream
Last Tracked
Nov 11, 2026
Daily AI digest
AI Retail Discussion Summary:
The latest Yahoo Finance news highlights four commercial-stage biotechs, including Madrigal Pharmaceuticals ($MDGL), with established marketed therapies and potential for sustained revenue growth. The article specifically mentions $MDGL's focus on increasing product adoption, broadening patient access, and strengthening existing franchises.
Key Retail Themes:
commercial-stage biotechs
sustained revenue growth
product adoption
patient access
Aggregated from r/wallstreetbets, r/stocks & StockTwits streams.
View All Trending Reddit & WSB Stocks →
Last updated: November 11, 2026 5:19 AM ET
Data refreshes hourly during market hours. Next update: 6:19 AM
Data refreshes hourly during market hours. Next update: 6:19 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is MDGL showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ONC
BeOne Medicines AG |
STRONG BUY
27 analysts |
$438 | 40 SELL |
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
30 analysts |
$302 | 49 HOLD |
|
VRTX
Vertex Pharmaceuticals I… |
STRONG BUY
32 analysts |
$592 | 37 SELL |
|
ORIC
Oric Pharmaceuticals Inc |
STRONG BUY
15 analysts |
$22 | 72 BUY |
|
IDYA
Ideaya Biosciences Inc |
STRONG BUY
16 analysts |
$51 | 62 BUY |
Advanced MDGL Option Strategies
Professional options setups generated by AI based on today's MDGL price and gamma walls.
Explore More Analysis & Live Quant Tools
Part A: Deep-Dive MDGL Research Pages
